Global Treatment for Gastroparesis Market Size, Share, and Trends Analysis Report, By Drug Type (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxic Injections), By Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, and Post-Surgical Gastroparesis), and By End User (Hospitals, Clinics, and Others) Forecast (2022-2028)

The treatment for gastroparesis market is anticipated to grow at a significant CAGR of 3.4% during the forecast period (2022-2028). Gastroparesis is a gastrointestinal medical disorder that inhibits the natural spontaneous motility of the stomach muscles. It interferes with regular digestion, produces vomiting, and creates issues with blood sugar and nutrition. Gastroparesis is treated with a variety of pharmaceuticals and treatments, including Reglan, erythromycin, antiemetics, and others. The growth of the market is driven by an increasing number of operations that result in postsurgical gastroparesis, as well as the rise in the diabetic and geriatric population, and the development of innovative medications to treat symptoms including nausea and vomiting.

The global treatment for gastroparesis market is segmented based on drug type, disease type, and end-user. Based on type, the market is sub-segmented into prokinetic agents, antiemetic agents, and botulinum toxic injections. Based on the disease type, the market is sub-segmented into diabetic gastroparesis, idiopathic gastroparesis, and post-surgical gastroparesis. Among these disease types, the idiopathic gastroparesis segment is expected to propel the growth of the market. It is a form of gastroparesis that happens for no apparent reason. Nausea, vomiting, early satiety, postprandial fullness, and upper abdominal discomfort are the primary symptoms of this kind of gastroparesis, with abdominal pain being the most common. Dietary changes, prokinetic medicines, antiemetic pharmacological treatment, and symptom modulators can all help with this illness. Prokinetics drugs increase stomach motility, antiemetic drugs reduce nausea and vomiting, and symptom modulators, such as psychotropic drugs lower symptom manifestation. Nonsteroidal anti-inflammatory medicines (NSAIDs) may also aid in the management of stomach discomfort. Based on the end-user, the market is sub-segmented into hospitals, pharmacies, clinics, and others.

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.  For instance, in October 2020, Evoke Pharma Inc. and Eversana Ltd. announced the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms of acute and recurrent diabetic gastroparesis in adults.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Type
  • By Disease Type
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Allergan PLC, Abbott Laboratories Ltd., AstraZeneca PLC, Cadila Pharmaceuticals Ltd., GlaxoSmithKline PLC, Neurogastrx Inc., and Theravance Biopharma Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Treatment for Gastroparesis Market Report by Segment

By Drug Type

• Prokinetic Agents
• Antiemetic Agents
• Botulinum Toxic Injections

By Disease Type

• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Post-Surgical Gastroparesis

By End-User

• Hospitals
• Clinics
• Others

Global Treatment for Gastroparesis Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa